A comprehensive view of Quanterix Corp.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Quanterix's Simoa p-Tau 217 blood test to aid in diagnosing Alzheimer's disease receives Breakthrough Device designation from the FDA; p-Tau 217 has emerged as a top-performing biomarker for Alzheimer’s pathology
Published: March 06, 2024 by Quanterix Corp.
AdventHealth collaborates with Quanterix Corporation, Mayo Clinic and other health systems to enhance Alzheimer's diagnosis using Quanterix's blood biomarker tests for accessible, non-invasive detection methods
Published: March 06, 2024 by AdventHealth

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count